This multidisciplinary effort of experts in biomarker research proposes to renew their commitment to the EDRN and to lead our Clinical Validation Center ever closer to impacting patient care. Therefore we propose to test best candidate biomarkers of lung cancer developed at our and other institutions for added value in the assessment of the risk for, and diagnosis of, lung cancer compared to the standard of care. The hypothesis is that addition of imaging and molecular biomarkers measured by chest computed tomography and in the sputum, the bronchial epithelium and blood, likely in a multivariable manner, could improve the identification of high risk individuals for lung cancer and improve CT screening overall results by reducing false-positive tests. We propose a three way approach. First we will test candidate biomarkers for lung cancer development in an observational study of selected very high risk individuals from the Nashville community performing repeated measurements of clinical, imaging (low-dose chest CT) variables, as well as molecular biomarker signatures, some of which will be obtained from bronchoscopy. Second, we propose to validate the most promising diagnostic candidate signatures to each test in carefully designed prospective study of individuals presenting with indeterminate pulmonary nodules. Third, we will test a novel molecular imaging tracer in a population of intermediate and high risk lung nodules. This tracer will be compared to standard of care FDG PET, and if significantly better, should have huge impact on the management of lung nodules. Our CVC will also centralize an effort to collect and store pertinent clinical data and tissues (blood, urine, and the airways specimens) and make these resources available to the community and to collaborators within and outside of the EDRN program, including the industry partners.

Public Health Relevance

There is no currently perfect strategy for the early detection of lung cancer. We propose to put to the test a multidisciplinary approach for early detection of lung cancer, including the selection of the population with a validated clinical predictor rule, an to determine specifically the added value of molecular biomarkers to clinical and chest CT predictors of risk. If proven beneficial, this strategy may be suitable for validation in larger trals.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Krueger, Karl E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
United States
Zip Code
Ajona, Daniel; Okrój, Marcin; Pajares, María J et al. (2018) Complement C4d-specific antibodies for the diagnosis of lung cancer. Oncotarget 9:6346-6355
Li, Qian; Balagurunathan, Yoganand; Liu, Ying et al. (2018) Comparison Between Radiological Semantic Features and Lung-RADS in Predicting Malignancy of Screen-Detected Lung Nodules in the National Lung Screening Trial. Clin Lung Cancer 19:148-156.e3
Deppen, Stephen Andrew; Massion, Pierre P; Blume, Jeffrey et al. (2018) Accuracy of a novel histoplasmosis enzyme immunoassay to evaluate suspicious lung nodules. Cancer Epidemiol Biomarkers Prev :
Magarik, Meaghan A; Walker, Ronald C; Gilbert, Jill et al. (2018) Intracardiac Metastases Detected by 18F-FSPG PET/CT. Clin Nucl Med 43:28-30
Codreanu, Simona G; Hoeksema, Megan D; Slebos, Robbert J C et al. (2017) Identification of Proteomic Features To Distinguish Benign Pulmonary Nodules from Lung Adenocarcinoma. J Proteome Res 16:3266-3276
Li, Qian; Kim, Jongphil; Balagurunathan, Yoganand et al. (2017) Imaging features from pretreatment CT scans are associated with clinical outcomes in nonsmall-cell lung cancer patients treated with stereotactic body radiotherapy. Med Phys 44:4341-4349
Massion, Pierre P; Healey, Graham F; Peek, Laura J et al. (2017) Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer. J Thorac Oncol 12:578-584
Walker, Ronald; Deppen, Stephen; Smith, Gary et al. (2017) 68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer. PLoS One 12:e0171301
Mazzone, Peter J; Sears, Catherine Rufatto; Arenberg, Doug A et al. (2017) Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement. Am J Respir Crit Care Med 196:e15-e29
Liu, Ying; Balagurunathan, Yoganand; Atwater, Thomas et al. (2017) Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules. Clin Cancer Res 23:1442-1449

Showing the most recent 10 out of 38 publications